16:34 EST Verastem (VSTM) jumps 50% to $5.50 on FDA priority review for Avutometinib
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem price target raised to $9 from $7 at Mizuho
- Verastem announces preliminary avutometinib and sotorasib data
- Verastem Inc. Reports Increased Operating Expenses and Net Loss
- Verastem price target lowered to $14 from $20 at Alliance Global Partners
- Verastem cuts FY24 EPS view to $4.17-$4.23 from $4.25-$4.35, consensus $4.28